serine/threonine kinase 11
Zuletzt aktualisiert 2. Mai 2023
Erfüllt die redaktionelle Richtlinien
- HerunterladenHerunterladen
- Teilen
- Language
- Diskussion
- Audio-Version
- Zu bevorzugten Quellen bei Google hinzufügen
Der STK11 gene (also called LKB1) provides instructions for making an enzyme called serine/threonine kinase 11. This enzyme is a tumour suppressor, which means that it helps keep cells from growing and dividing too fast or in an uncontrolled way. This enzyme helps certain types of cells correctly orient themselves within tissues (polarization) and assists in determining the amount of energy a cell uses. This kinase also promotes a type of programmed cell death known as apoptosis. In addition to its role as a tumour suppressor, serine/threonine kinase 11 function appears to be required for normal development before birth.
Normal function
Der STK11 gene (also called LKB1) provides instructions for making an enzyme called serine/threonine kinase 11. This enzyme is a tumour suppressor, which means that it helps keep cells from growing and dividing too fast or in an uncontrolled way. This enzyme helps certain types of cells correctly orient themselves within tissues (polarization) and assists in determining the amount of energy a cell uses. This kinase also promotes a type of programmed cell death known as apoptosis. In addition to its role as a tumour suppressor, serine/threonine kinase 11 function appears to be required for normal development before birth.
Conditions referring to this gene or chromosome
Other names
LKB1
PJS
serine/threonine kinase 11 (Peutz-Jeghers syndrome)
Serine/threonine-protein kinase 11
STK11_HUMAN
Related patient information and medicines
Patient information leaflet
Glykogenspeicherkrankheiten
Glykogenspeicherkrankheiten are a group of inherited diseases. They result from a problem with one of the proteins (known as enzymes) involved in the conversion of glucose to glycogen, or the breakdown of glycogen back into glucose. They mostly tend to affect your liver and muscles. Most are diagnosed in childhood. Symptoms include weakness,.
Patient information leaflet
Primärer Leberkrebs
It is not likely to be curative for primary liver cancer but may shrink the tumour down to slow the progression of the disease. There are new medicines being developed for the treatment of liver cancer. For example, sorafenib is a type of medicine called a multi-targeted kinase inhibitor. It interferes with the growth of cancer cells. Research has.
Patient information leaflet
Muskeldystrophie
Usu... Also, if a child has delayed motor milestones (as mentioned above), a doctor may advise testing for MD, even though the problem could be due to another cause. MD may be diagnosed using one or more of the following tests: A blood test for creatine kinase (CK) - in many types of MD, the blood level of CK is very high. A muscle biopsy - this.
Patient information leaflet
Down-Syndrom-Screening
The rest of this leaflet concentrates on Untersuchung for. What is the difference between a screening test and a diagnostic test for Down's syndrome. There are two different types of tests that can be done to look for Down's syndrome during pregnancy - a screening test and a diagnostic test. See also Pregnancy screening tests. As mentioned above,.
Patient information leaflet
Eileiterschwangerschaft
An ectopic pregnancy is a pregnancy which is not in the womb - the normal place. Ectopic means 'misplaced'. It occurs in about 11 in 1,000 pregnancies. Although many ectopic pregnancies are now treated without the need for an operation, you should always see a doctor urgently if you think you have an ectopic pregnancy symptoms. Symptoms include.
Patient information leaflet
Narkolepsie und Kataplexie
Narkolepsie ist a long-term (chronic) problem that affects your sleep. You feel excessively tired during the daytime but have disturbed night-time sleep. You can also have sleep attacks where you fall asleep during the day without any warning. Many people with narcolepsy also have cataplexy. This is a condition in which you have sudden loss of.
Weiterführende Lektüre und Referenzen
- serine/threonine kinase 11; MedlinePlus, National Library of Medicine.
- Amos CI, Wagner A. Peutz-Jeghers Syndrome. 2001 Feb 23 [updated 2026 Oct 6]. In: Adam MP, Bick S, Mirzaa GM, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from http://www.ncbi.nlm.nih.gov/books/NBK1266/
- Hardie DG, Alessi DR. LKB1 and AMPK and the cancer-metabolism link - ten years after. BMC Biol. 2013 Apr 15;11:36. doi: 10.1186/1741-7007-11-36.
- Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A, Bignell G, Warren W, Aminoff M, Hoglund P, Jarvinen H, Kristo P, Pelin K, Ridanpaa M, Salovaara R, Toro T, Bodmer W, Olschwang S, Olsen AS, Stratton MR, de la Chapelle A, Aaltonen LA. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature. 1998 Jan 8;391(6663):184-7. doi: 10.1038/34432.
- National Cancer Institute: Genetics of Breast and Gynecologic Cancers (PDQ®)–Health Professional Version
- Vaahtomeri K, Makela TP. Molecular mechanisms of tumor suppression by LKB1. FEBS Lett. 2011 Apr 6;585(7):944-51. doi: 10.1016/j.febslet.2010.12.034. Epub 2010 Dec 27.
- Weissman SM, Weiss SM, Newlin AC. Genetic testing by cancer site: ovary. Cancer J. 2012 Jul-Aug;18(4):320-7. doi: 10.1097/PPO.0b013e31826246c2.
- Wingo SN, Gallardo TD, Akbay EA, Liang MC, Contreras CM, Boren T, Shimamura T, Miller DS, Sharpless NE, Bardeesy N, Kwiatkowski DJ, Schorge JO, Wong KK, Castrillon DH. Somatic LKB1 mutations promote cervical cancer progression. PLoS One. 2009;4(4):e5137. doi: 10.1371/journal.pone.0005137. Epub 2009 Apr 2.
- Zhuang ZG, Di GH, Shen ZZ, Ding J, Shao ZM. Enhanced expression of LKB1 in breast cancer cells attenuates angiogenesis, invasion, and metastatic potential. Mol Cancer Res. 2006 Nov;4(11):843-9. doi: 10.1158/1541-7786.MCR-06-0118.
Artikelverlauf
Artikel auch verfügbar in Englisch, Deutsch, Spanisch, Französisch, Italienisch, Portugiesisch, Hindi, Hebräisch, Arabisch, und Schwedisch.
2. Mai 2023 | Neueste Version
1 May 2015 | Ursprünglich veröffentlicht
Nehmen Sie an der Diskussion teil
Teilen Sie Ihre Gedanken oder Erfahrungen mit anderen in unserem Patientengemeinschaften.
Fragen, teilen, verbinden.
Durchsuchen Sie Diskussionen, stellen Sie Fragen und teilen Sie Erfahrungen zu Hunderten von Gesundheitsthemen.
Abonnieren Sie den Patienten-Newsletter
Ihre wöchentliche Dosis klarer, vertrauenswürdiger Gesundheitsberatung - geschrieben, um Ihnen zu helfen, sich informiert, selbstbewusst und in Kontrolle zu fühlen.
Durch das Abonnieren akzeptieren Sie unsere Datenschutzrichtlinie. Sie können sich jederzeit abmelden. Wir verkaufen Ihre Daten niemals.